Cargando…
Molecular Testing in Ovarian Tumours: Challenges from the Pathologist’s Perspective
The use of molecular testing to direct diagnosis and treatment options in ovarian tumours has rapidly expanded in recent years, in particular with regard to the recommendation for routine homologous recombination deficiency (HRD) testing in all patients with high-grade ovarian epithelial tumours. Th...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297009/ https://www.ncbi.nlm.nih.gov/pubmed/37370967 http://dx.doi.org/10.3390/diagnostics13122072 |
_version_ | 1785063781972312064 |
---|---|
author | Dinneen, Kate Arora, Rupali |
author_facet | Dinneen, Kate Arora, Rupali |
author_sort | Dinneen, Kate |
collection | PubMed |
description | The use of molecular testing to direct diagnosis and treatment options in ovarian tumours has rapidly expanded in recent years, in particular with regard to the recommendation for routine homologous recombination deficiency (HRD) testing in all patients with high-grade ovarian epithelial tumours. The implications of this increased level of testing upon the pathologist is significant in terms of increased workload, the provision of adequate tumour samples for molecular testing, and the interpretation of complex molecular pathology reports. In order to optimise the quality of reports generated, it is important to establish clear pathways of communication on both a local and national level between clinicians, pathology lab staff, and medical scientists. On a national level, in the United Kingdom, Genomic Laboratory Hubs (GLHs) have been established to provide a uniform high-quality molecular diagnostics service to all patients with ovarian tumours within the National Health services in the country. On a local level, there are a number of small steps that can be taken to improve the quality of tissues available for testing and to streamline the processes involved in generating requests for molecular testing. This article discusses these factors from the perspective of the clinical histopathologist. |
format | Online Article Text |
id | pubmed-10297009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102970092023-06-28 Molecular Testing in Ovarian Tumours: Challenges from the Pathologist’s Perspective Dinneen, Kate Arora, Rupali Diagnostics (Basel) Review The use of molecular testing to direct diagnosis and treatment options in ovarian tumours has rapidly expanded in recent years, in particular with regard to the recommendation for routine homologous recombination deficiency (HRD) testing in all patients with high-grade ovarian epithelial tumours. The implications of this increased level of testing upon the pathologist is significant in terms of increased workload, the provision of adequate tumour samples for molecular testing, and the interpretation of complex molecular pathology reports. In order to optimise the quality of reports generated, it is important to establish clear pathways of communication on both a local and national level between clinicians, pathology lab staff, and medical scientists. On a national level, in the United Kingdom, Genomic Laboratory Hubs (GLHs) have been established to provide a uniform high-quality molecular diagnostics service to all patients with ovarian tumours within the National Health services in the country. On a local level, there are a number of small steps that can be taken to improve the quality of tissues available for testing and to streamline the processes involved in generating requests for molecular testing. This article discusses these factors from the perspective of the clinical histopathologist. MDPI 2023-06-15 /pmc/articles/PMC10297009/ /pubmed/37370967 http://dx.doi.org/10.3390/diagnostics13122072 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Dinneen, Kate Arora, Rupali Molecular Testing in Ovarian Tumours: Challenges from the Pathologist’s Perspective |
title | Molecular Testing in Ovarian Tumours: Challenges from the Pathologist’s Perspective |
title_full | Molecular Testing in Ovarian Tumours: Challenges from the Pathologist’s Perspective |
title_fullStr | Molecular Testing in Ovarian Tumours: Challenges from the Pathologist’s Perspective |
title_full_unstemmed | Molecular Testing in Ovarian Tumours: Challenges from the Pathologist’s Perspective |
title_short | Molecular Testing in Ovarian Tumours: Challenges from the Pathologist’s Perspective |
title_sort | molecular testing in ovarian tumours: challenges from the pathologist’s perspective |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297009/ https://www.ncbi.nlm.nih.gov/pubmed/37370967 http://dx.doi.org/10.3390/diagnostics13122072 |
work_keys_str_mv | AT dinneenkate moleculartestinginovariantumourschallengesfromthepathologistsperspective AT arorarupali moleculartestinginovariantumourschallengesfromthepathologistsperspective |